glp-1 levels in type 2 diabetes Receptor Agonists as Treatments for GLP-1 Agonists Liraglutide Improved Vascular
Description
The GLP-1 analogues market is benefiting from rapid innovation in drug delivery, formulation, and molecular design
ER Unfolded Protein Response A cellular condition on which metabolically mediated and inflammation-driven pathologies converge is ER stress and the associated UPR
The use of incretin mimetics is also recommended as add-on therapy in people with type 2 diabetes and obesity when initial therapy provides insufficient glycaemic control.
Leg pain is not listed as a frequent side effect in Ozempic clinical trials, but some patients report musculoskeletal discomfort during GLP-1 therapy
2016;28:jne.12433
